Business
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gYus8wVug.f5B64LYYJN7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/gYus8wVug.f5B64LYYJN7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.","length":411,"tagName":"p"},{"type":"text","content":"The gross proceeds of the offering are approximately $2.0 million (the "Offering").","length":93,"tagName":"p"},{"type":"text","content":"D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.","length":81,"tagName":"p"},{"type":"text","content":"The closing of the Offering is expected to occur on or about May 21, 2026, subject to the satisfaction of customary closing conditions.","length":135,"tagName":"p"},{"type":"text","content":"The shares of common stock are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026.","length":263,"tagName":"p"},{"type":"text","content":"A prospectus supplement describing the terms of the proposed registered direct offering will be filed with the SEC. Once filed, it will be available on the SEC’s website at http://www.sec.gov. A copy of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained, when available, from D. Boral Capital LLC, 59...